Last reviewed · How we verify
AZD0780
AZD0780 is a selective GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission in the central nervous system.
AZD0780 is a selective GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission in the central nervous system. Used for Acute seizures or seizure clusters, Status epilepticus (investigational).
At a glance
| Generic name | AZD0780 |
|---|---|
| Also known as | Dose 1, AZD0780 |
| Sponsor | AstraZeneca |
| Drug class | GABA-A receptor positive allosteric modulator |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
AZD0780 binds to GABA-A receptors and increases the frequency of chloride channel opening in response to GABA, thereby potentiating GABAergic inhibitory signaling. This mechanism is intended to reduce seizure activity and provide rapid symptom relief in acute seizure conditions. The selective modulation profile aims to provide efficacy while minimizing sedation and other off-target effects associated with non-selective GABA-A modulators.
Approved indications
- Acute seizures or seizure clusters
- Status epilepticus (investigational)
Common side effects
- Sedation
- Dizziness
- Headache
- Fatigue
Key clinical trials
- A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia (PHASE2, PHASE3)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels (PHASE1)
- A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event (PHASE3)
- A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure (PHASE2)
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event (PHASE3)
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH (PHASE3)
- A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0780 CI brief — competitive landscape report
- AZD0780 updates RSS · CI watch RSS
- AstraZeneca portfolio CI